BioLife Solutions (NASDAQ:BLFS) Faces Downgrade Amidst Repligen Acquisition and Shareholder Scrutiny

• An analyst from Lake Street has downgraded BioLife Solutions (NASDAQ:BLFS) stock to a 'Hold' rating, setting a price target of $31.00.
• The downgrade coincides with a proposed acquisition of BioLife Solutions by Repligen Corporation (NASDAQ:RGEN) in a cash-and-stock deal valued at approximately $1.5 billion.
• The merger and acquisition terms are under investigation by Halper Sadeh LLC, questioning the fair price for BioLife Solutions shareholders, especially given GuruFocus's fair value estimate of $28.93.

BioLife Solutions (NASDAQ:BLFS) is a company that supplies tools and services for the cell and gene therapy industry. It develops and markets preservation media products and automated thawing devices for cells, tissues, and organs. Its competitor, Repligen Corporation (NASDAQ:RGEN), is also active in the bioprocessing market and seeks to expand its footprint.

On July 22, 2026, an analyst from Lake Street sets a price target of $31.00 for BioLife Solutions. This is accompanied by a stock downgrade of the company's stock to a 'Hold' rating from a 'Buy'. A 'Hold' rating suggests that the analyst believes the stock will perform in line with the market, with limited upside.

The analyst's rating change coincides with the news of a proposed acquisition of BioLife Solutions by Repligen Corporation. As reported by Reuters, the merger and acquisition deal is a cash-and-stock deal valued at approximately $1.5 billion. At the time of the analyst's announcement, BioLife Solutions stock is trading at $31.20 per share.

The terms of the sale are now under investigation by the investor rights law firm Halper Sadeh LLC. The firm questions if the deal, which offers $11.25 in cash plus 0.1442 shares of Repligen Corporation stock, provides a fair price to BioLife Solutions shareholders.

The shareholder investigation centers on whether the board of directors breached its fiduciary duties. This is the board's legal obligation to act in the best financial interest of shareholders. As highlighted by GuruFocus, its fair value estimate for BioLife Solutions is $28.93, which is significantly higher than the price offered in the acquisition.